153 related articles for article (PubMed ID: 20306185)
1. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.
Kim KA; Park JY
Eur J Clin Pharmacol; 2010 Jul; 66(7):721-5. PubMed ID: 20306185
[TBL] [Abstract][Full Text] [Related]
2. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Shimizu M; Uno T; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
[TBL] [Abstract][Full Text] [Related]
3. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
Tateishi T; Miura M; Suzuki T; Uno T
Br J Clin Pharmacol; 2008 May; 65(5):693-700. PubMed ID: 18294330
[TBL] [Abstract][Full Text] [Related]
4. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim KA; Park PW; Park JY
Eur J Clin Pharmacol; 2009 Jun; 65(6):609-14. PubMed ID: 19221726
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
Sakugawa T; Miura M; Hokama N; Suzuki T; Tateishi T; Uno T
Br J Clin Pharmacol; 2009 May; 67(5):535-40. PubMed ID: 19552748
[TBL] [Abstract][Full Text] [Related]
6. Effects of breviscapine and C3435T
Zhao Y; Miao Z; Jiang M; Zhou X; Lai Y
Xenobiotica; 2021 Mar; 51(3):366-372. PubMed ID: 33256506
[TBL] [Abstract][Full Text] [Related]
7. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
Saruwatari J; Yasui-Furukori N; Niioka T; Akamine Y; Takashima A; Kaneko S; Uno T
J Clin Psychopharmacol; 2012 Apr; 32(2):195-9. PubMed ID: 22367658
[TBL] [Abstract][Full Text] [Related]
8. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Yasui-Furukori N; Kojima M; Uno T
Br J Clin Pharmacol; 2012 Mar; 73(3):478-81. PubMed ID: 21950458
[TBL] [Abstract][Full Text] [Related]
9. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
Bedada SK; Boga PK
Eur J Clin Pharmacol; 2017 Mar; 73(3):343-349. PubMed ID: 27981349
[TBL] [Abstract][Full Text] [Related]
10. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.
Akamine Y; Miura M; Yasui-Furukori N; Ieiri I; Uno T
J Clin Pharm Ther; 2015 Feb; 40(1):98-103. PubMed ID: 25263393
[TBL] [Abstract][Full Text] [Related]
11. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
[TBL] [Abstract][Full Text] [Related]
12. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.
Zhou Q; Ye Z; Ruan Z; Zeng S
J Ethnopharmacol; 2013 Apr; 146(3):744-9. PubMed ID: 23422332
[TBL] [Abstract][Full Text] [Related]
13. Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
Pinto L; Moreira FL; Nardotto GHB; Cavalli RC; Moisés ECD; Duarte G; Lanchote VL
Pharm Res; 2020 Jun; 37(7):131. PubMed ID: 32557079
[TBL] [Abstract][Full Text] [Related]
14. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
[TBL] [Abstract][Full Text] [Related]
15. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
[TBL] [Abstract][Full Text] [Related]
16. The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers.
Bedada SK; Boga PK; Kotakonda HK
Xenobiotica; 2017 Mar; 47(3):230-235. PubMed ID: 27151911
[TBL] [Abstract][Full Text] [Related]
17. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
Drescher S; Schaeffeler E; Hitzl M; Hofmann U; Schwab M; Brinkmann U; Eichelbaum M; Fromm MF
Br J Clin Pharmacol; 2002 May; 53(5):526-34. PubMed ID: 11994059
[TBL] [Abstract][Full Text] [Related]
18. Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.
Turkanovic J; Ward MB; Gerber JP; Milne RW
Drug Metab Dispos; 2017 May; 45(5):569-575. PubMed ID: 28188296
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell T; Stoltz M; Weir S
Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
[TBL] [Abstract][Full Text] [Related]
20. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
